Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lerociclib
- Development stage
- Phase 3
- Lead developer
- G1 Therapeutics
- Modality
- Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Lerociclib is an orally bioavailable small molecule inhibitor of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6), developed primarily for the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. It acts by selectively inhibiting CDK4/6 activity, thereby blocking cell cycle progression from the G1 to S phase in tumor cells dependent on this pathway. Lerociclib has demonstrated antineoplastic activity and a differentiated safety profile in clinical trials. It is being investigated both as monotherapy and in combination with endocrine therapies such as fulvestrant or letrozole[2][3][9][10].
- Other names
- G1T38 free baseG-1T38 free baseG 1T38 free base
02
Targets
CDK6 (Cyclin-dependent kinase 6)P-TEFb (Positive transcription elongation factor b)CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on lerociclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lerociclib.